Related Experiment Video
Updated: Dec 13, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle-based Chemotherapy in Pten-deleted
Rebecca D Dodd1, Amanda Scherer2, Wesley Huang3
1Department of Internal Medicine, University of Iowa, Iowa City, Iowa. rebecca-dodd@uiowa.edu david.kirsch@duke.edu.
Purpose:
Nanoparticle-encapsulated drug formulations can improve responses to conventional chemotherapy by increasing drug retention within the tumor and by promoting a more effective antitumor immune response than free drug. New drug delivery modalities are needed in sarcomas because they are often chemoresistant cancers, but the rarity of sarcomas and the complexity of diverse subtypes makes it challenging to investigate novel drug formulations.
Experimental Design:
New drug formulations can be tested in animal models of sarcomas where the therapeutic response of different formulations can be compared using mice with identical tumor-initiating mutations. Here, using Cre/loxP and CRISPR/Cas9 techniques, we generated two distinct mouse models of Pten-deleted soft-tissue sarcoma: malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma (UPS). We used these models to test the efficacy of chimeric polypeptide doxorubicin (CP-Dox), a nanoscale micelle formulation, in comparison with free doxorubicin.
Results:
The CP-Dox formulation was superior to free doxorubicin in MPNST models. However, in UPS tumors, CP-Dox did not improve survival in comparison with free doxorubicin. While CP-Dox treatment resulted in elevated intratumoral doxorubicin concentrations in MPNSTs, this increase was absent in UPS tumors. In addition, elevation of CD8+ T cells was observed exclusively in CP-Dox-treated MPNSTs, although these cells were not required for full efficacy of the CP nanoparticle-based chemotherapy.
Conclusions:
These results have important implications for treating sarcomas with nanoparticle-encapsulated chemotherapy by highlighting the tumor subtype-dependent nature of therapeutic response.
Insights
Nanoparticle drug delivery shows promise for sarcoma treatment, but efficacy varies by tumor subtype. Chimeric polypeptide doxorubicin (CP-Dox) improved outcomes in malignant peripheral nerve sheath tumors but not undifferentiated pleomorphic sarcomas.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Sarcomas are chemoresistant cancers requiring novel therapeutic strategies.
- Nanoparticle-encapsulated drugs offer potential advantages over free drugs in cancer therapy.
- Investigating new drug formulations for rare and diverse sarcoma subtypes is challenging.
Purpose of the Study:
- To evaluate the efficacy of nanoparticle-encapsulated doxorubicin (CP-Dox) in distinct sarcoma subtypes.
- To compare CP-Dox with free doxorubicin in preclinical mouse models of sarcoma.
- To elucidate the impact of nanoparticle drug delivery on tumor microenvironment and immune response.
Main Methods:
- Generation of two distinct mouse models of Pten-deleted soft-tissue sarcoma (MPNST and UPS) using Cre/loxP and CRISPR/Cas9.
- Administration of chimeric polypeptide doxorubicin (CP-Dox) and free doxorubicin to tumor-bearing mice.
- Assessment of therapeutic efficacy, intratumoral drug concentration, and immune cell infiltration (CD8+ T cells).
Main Results:
- CP-Dox demonstrated superior efficacy compared to free doxorubicin in malignant peripheral nerve sheath tumor (MPNST) models.
- CP-Dox did not improve survival in undifferentiated pleomorphic sarcoma (UPS) models compared to free doxorubicin.
- Elevated intratumoral doxorubicin concentrations and CD8+ T cell infiltration were observed in CP-Dox treated MPNSTs but not UPS tumors.
Conclusions:
- Therapeutic response to nanoparticle-encapsulated chemotherapy in sarcomas is dependent on tumor subtype.
- These findings highlight the need for tailored nanoparticle drug delivery strategies for different sarcoma types.
- Further research into nanoparticle formulations for chemoresistant sarcomas is warranted.
